Product
Topotecan
Aliases
Evotopin, Hycamptamine, Hycamptin, hycamtin, Hycamtin (12 other aliases)
Name
Topotecan Hydrochloride
FDA Approved
Yes
63 clinical trials
5 organizations
178 indications
2 documents
Indication
Ewing SarcomaIndication
Solid TumorsIndication
Rhabdoid TumorIndication
RhabdomyosarcomaIndication
NeuroblastomaIndication
MedulloblastomaIndication
Diffuse Intrinsic Pontine GliomaIndication
Refractory CancerIndication
Refractory NeoplasmIndication
Pediatric CancerIndication
Refractory TumorIndication
Pediatric Brain TumorIndication
Neuroblastoma RecurrentIndication
LymphomaIndication
Pediatric MeningiomaIndication
Ovarian CancerIndication
Small Cell Lung CancerIndication
Fallopian tube cancerIndication
Primary Peritoneal CancerIndication
Platinum-resistant Ovarian CancerIndication
Low Grade Serous Ovarian CancerIndication
Acute Myeloid LeukemiaIndication
Acute Lymphoblastic LeukemiaIndication
Small Cell Lung CarcinomaIndication
Cervical CancerIndication
Lung CancerIndication
Advanced CancerIndication
cervical cancerIndication
lung cancerIndication
Myxoid LiposarcomaIndication
Soft Tissue SarcomaIndication
Desmoplastic Small Round Cell TumorIndication
Extraskeletal Myxoid ChondrosarcomaIndication
Angiomatoid Fibrous HistiocytomaIndication
Clear Cell SarcomaIndication
Primary Pulmonary Myxoid SarcomaIndication
Myoepithelial TumorIndication
Sclerosing Epithelioid FibrosarcomaIndication
Fibromyxoid tumorIndication
Extensive-stage Small-cell Lung CancerIndication
Advanced Solid TumorIndication
Endometrial CancerIndication
fallopian tube carcinomaIndication
Primary Peritoneal CarcinomaIndication
Wilms TumorIndication
cancerIndication
Small CellIndication
Fallopian Tube CarcinomaIndication
Platinum-Refractory Ovarian CarcinomaIndication
Endometrioid AdenocarcinomaIndication
High-Grade Serous AdenocarcinomaIndication
Ovarian Endometrioid AdenocarcinomaIndication
Ovarian High Grade Serous AdenocarcinomaIndication
Platinum-Resistant Ovarian CarcinomaIndication
Atypical chronic myeloid leukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Essential ThrombocythemiaIndication
MyelofibrosisIndication
Polycythemia VeraIndication
Recurrent Acute Myeloid LeukemiaIndication
Solid TumorIndication
Adult RhabdomyosarcomaIndication
Soft tissue sarcomaIndication
Mixed Germ Cell Tumor of the OvaryIndication
Recurrent Adult Brain TumorIndication
Extensive-stage small cell lung cancerIndication
Limited-Stage Lung Small Cell CarcinomaIndication
Recurrent Lung Small Cell CarcinomaIndication
Low Grade Serous AdenocarcinomaIndication
Ovarian Clear Cell AdenocarcinomaIndication
Low Grade Serous Ovarian AdenocarcinomaIndication
Ovarian Mucinous AdenocarcinomaIndication
Recurrent Ovarian Seromucinous CarcinomaIndication
High Grade Serous Ovarian AdenocarcinomaIndication
Ovarian Seromucinous CarcinomaIndication
Ovarian Transitional Cell CarcinomaIndication
High Grade Serous AdenocarcinomaIndication
Peritoneal Undifferentiated CarcinomaIndication
Childhood Brain Stem GliomaIndication
Childhood AstrocytomaIndication
Childhood EpendymomaIndication
Germ Cell TumorIndication
Childhood MedulloblastomaIndication
PineoblastomaIndication
Childhood Visual Pathway GliomaIndication
Recurrent extragonadal germ cell tumorIndication
Ovarian Germ Cell TumorIndication
Wilms tumorIndication
solid tumorIndication
Protocol SpecificIndication
Childhood Solid TumorIndication
Non-Small Cell LungIndication
High Risk NeuroblastomaIndication
NeuroendocrineIndication
Small Cell CarcinomaIndication
Eye CancerIndication
RetinoblastomaIndication
Clear Cell AdenocarcinomaIndication
Metastatic Malignant Solid NeoplasmIndication
Metastatic Neuroendocrine CarcinomaIndication
Pancreatic CancerIndication
Stage III Lung Cancer AJCC v8Indication
Stage III Pancreatic CancerIndication
Stage IV Lung CancerIndication
Malignant Solid NeoplasmIndication
Neuroendocrine CarcinomaIndication
Pancreatic AdenocarcinomaIndication
Choroid Plexus PapillomaIndication
Choroid Plexus CarcinomaIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
NeoplasmIndication
Childhood Solid NeoplasmIndication
LeukemiaIndication
Brain GliomaIndication
Malignant NeoplasmIndication
Stage IV Cutaneous MelanomaIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Metastatic MelanomaIndication
Renal Cell CarcinomaIndication
Cutaneous MelanomaIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
Stage III Renal Cell Cancer AJCC v8Indication
Stage IIIA Lung CancerIndication
Stage IIIB Lung CancerIndication
Stage IV Renal Cell Cancer AJCC v8Indication
Lung Cancer Stage IVA AJCC v8Indication
Triple-Negative Breast CarcinomaIndication
melanomaIndication
Borderline Ovarian Serous TumorIndication
Micropapillary Serous CarcinomaIndication
Ovarian Serous AdenocarcinomaIndication
Primary Peritoneal Serous AdenocarcinomaIndication
acute myeloid leukemiaIndication
Ovarian clear cell adenocarcinomaIndication
Endometrioid ovarian adenocarcinomaIndication
Ovarian Undifferentiated CarcinomaIndication
OsteosarcomaIndication
Proliferative VitreoretinopathyIndication
Proliferative Vitreo-RetinopathyIndication
Retinal DetachmentIndication
NSCLCClinical trial
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORSStatus: Active (not recruiting), Estimated PCD: 2024-06-24
Clinical trial
Phase 1 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or With Irinotecan, Irinotecan Plus Temozolomide, or With Cyclophosphamide Plus Topotecan in Pediatric Patients With Refractory Malignancies.Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2022-04-13
Clinical trial
A Randomized, Double-blind, Phase III Study of BD0801 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Patients With Recurrent, Platinum-resistant Epithelial Ovarian, Fallopian Tube , or Primary Peritoneal Cancer.Status: Active (not recruiting), Estimated PCD: 2023-12-08
Clinical trial
A Multicenter, Randomized, Open-label, Parallel-design Phase 3 Study to Evaluate the Efficacy and Safety of LY01610 (Irinotecan Hydrochloride Liposome Injection) Versus Topotecan in Patients With Recurrent Small Cell Lung Cancer (SCLC)Status: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line ChemotherapyStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)Status: Recruiting, Estimated PCD: 2028-10-15
Clinical trial
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemias or Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-12-30
Clinical trial
DAREON™-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With Topotecan for the Treatment of Patients With Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-10-27
Clinical trial
A Two Part, Phase I-IIa Study Evaluating MK1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical CancerStatus: Terminated, Estimated PCD: 2011-06-13
Clinical trial
A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced MyelosuppressionStatus: Terminated, Estimated PCD: 2022-07-30
Clinical trial
A Phase II, Open-label, Single-arm Study of Berzosertib (M6620) in Combination With Topotecan in Participants With Relapsed Platinum-resistant Small-Cell Lung Cancer (DDRiver SCLC 250)Status: Completed, Estimated PCD: 2023-07-21
Clinical trial
A Phase 3 Trial of Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer After Platinum-Based Chemotherapy (BRAVA)Status: Withdrawn, Estimated PCD: 2021-10-22
Clinical trial
Phase I/II Multicenter Study to Assess Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2028-10-27
Clinical trial
An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)Status: Completed, Estimated PCD: 2018-08-17
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan ChemotherapyStatus: Recruiting, Estimated PCD: 2027-07-30
Clinical trial
Phase I Study to Evaluate the Mass Balance, PK, Metabolism and Excretion of Berzosertib (Intravenous) Containing Microtracer [14C]Berzosertib in Participants With Advanced Solid Tumors (DDRiver Solid Tumors 208)Status: Completed, Estimated PCD: 2023-06-28
Clinical trial
Open-label, Dose-escalation, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre Efficacy of BVAC-C in Patients With Multiple Metastatic Progressive or Recurrent HPV Type 16 or 18 Positive Cervical Cancer After Failure to Standard CareStatus: Completed, Estimated PCD: 2021-12-01
Clinical trial
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line TherapyStatus: Completed, Estimated PCD: 2022-02-08
Clinical trial
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select SarcomasStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic MalignanciesStatus: Terminated, Estimated PCD: 2021-07-30
Clinical trial
NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.Status: Completed, Estimated PCD: 2020-04-28
Clinical trial
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell CancersStatus: Recruiting, Estimated PCD: 2025-01-15
Clinical trial
A Phase I Study of Weekly Doxorubicin and Oral Topotecan for Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)Status: Completed, Estimated PCD: 2018-02-01
Clinical trial
N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk NeuroblastomaStatus: Recruiting, Estimated PCD: 2025-06-22
Clinical trial
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor TherapyStatus: Withdrawn, Estimated PCD: 2023-03-17
Clinical trial
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma TrialStatus: Active (not recruiting), Estimated PCD: 2021-08-01
Clinical trial
Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2023-12-30
Clinical trial
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)Status: Active (not recruiting), Estimated PCD: 2023-05-31
Clinical trial
Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent TumorsStatus: Active (not recruiting), Estimated PCD: 2013-01-19
Clinical trial
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2022-12-19
Clinical trial
A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersStatus: Active (not recruiting), Estimated PCD: 2021-02-24
Clinical trial
An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction ChemotherapyStatus: Terminated, Estimated PCD: 2023-08-28
Clinical trial
A Phase II Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma, With Randomization Depending on the Site of Relapse or on Previous TreatmentStatus: Terminated, Estimated PCD: 2023-05-22
Clinical trial
Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy.Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination With Topotecan and Pembrolizumab in Recurrent Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior BevacizumabStatus: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination With ChemotherapyStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)Status: Active (not recruiting), Estimated PCD: 2025-02-15
Clinical trial
Intra-Arterial (IA) Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma (ACPP) and Choroid Plexus Carcinoma (CPC) Prior to Second-Look SurgeryStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2019-01-13
Clinical trial
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaStatus: Completed, Estimated PCD: 2018-12-31
Clinical trial
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous LeukemiaStatus: Completed, Estimated PCD: 2005-10-01
Clinical trial
A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic BiopsyStatus: Terminated, Estimated PCD: 2023-05-24
Clinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2019-04-04
Clinical trial
A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer (SCLC): Topotecan Sequenced With Etoposide/Cisplatin, and Irinotecan/Cisplatin Sequenced With EtoposideStatus: Completed, Estimated PCD: 2012-01-01
Clinical trial
Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)Status: Completed, Estimated PCD: 2010-12-01
Clinical trial
A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2019-06-20
Clinical trial
Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or ComorbiditiesStatus: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Phase 1 Study of Cabozantinib in Combination With Topotecan-Cyclophosphamide for Patients With Relapsed Ewing Sarcoma or OsteosarcomaStatus: Completed, Estimated PCD: 2022-10-24
Clinical trial
Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube CancersStatus: Completed, Estimated PCD: 2023-04-24
Clinical trial
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative VitreoretinopathyStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior ChemotherapyStatus: Completed, Estimated PCD: 2017-05-15
Clinical trial
An Open-Label, Randomized, Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin in Patients Requiring Second-Line Chemotherapy for Small Cell Lung Cancer That is Refractory or Sensitive to First-Line Platinum-Based ChemotherapyStatus: Terminated, Estimated PCD: 2014-06-01
Organization
Fresenius Kabi USA, LLC
Organization
Accord Healthcare, Inc.Document
DailyMed Label: HYCAMTINOrganization
Novartis Pharmaceuticals CorporationOrganization
Accord Healthcare Inc.Organization
Actavis Pharma, Inc.